Lilly stock rises as China clears its weight-loss pill
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Eli Lilly and Co. (NYSE:LLY) rose 2.97% in premarket after China's medicine regulator approved its weight-loss pill orforglipron. The approval gives Lilly an edge over Novo Nordisk A/S (NYSE:NVO) in the world's second-largest…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishChina's approval of the orforglipron pill strengthens Lilly against Novo Nordisk.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Eli Lilly rose 2.97% premarket after China approved its weight-loss pill orforglipron.
- 02The pill will compete with once-weekly GLP-1 injections from Novo, Pfizer and Innovent.
- 03Novo's oral version of Wegovy has not yet been approved in China.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Eli Lilly and Company1,437.76 USDMarket closedtoday +0.38%Positive Novo Nordisk A/S41.09 USDMarket closedtoday +0.96%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets